KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)

被引:196
作者
Uhlig, Katrin [1 ]
Berns, Jeffrey S.
Kestenbaum, Bryan [3 ]
Kumar, Raj [4 ]
Leonard, Mary B. [2 ]
Martin, Kevin J. [5 ]
Sprague, Stuart M. [6 ]
Goldfarb, Stanley
机构
[1] Tufts Univ, Sch Med, Tufts Med Ctr, Boston, MA 02445 USA
[2] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA
[3] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA
[4] Mayo Clin, Coll Med, Rochester, MN USA
[5] St Louis Univ, Div Nephrol, St Louis, MO 63103 USA
[6] Univ Chicago, Pritzker Sch Med, N Shore Univ Hlth Syst, Chicago, IL 60637 USA
关键词
Clinical practice guideline; guideline adaptation; chronic kidney disease; mineral and bone disease; renal osteodystrophy; Kidney Disease Outcomes Quality Initiative (KDOQI); Kidney Disease: Improving Global Outcomes (KDIGO); ESRD PAYMENT PERSPECTIVES; CHRONIC KIDNEY-DISEASE; X PHOSPHATE PRODUCT; STAGE RENAL-DISEASE; QUALITY-OF-LIFE; VITAMIN-D; PROPOSED RULE; HEMODIALYSIS-PATIENTS; ALKALINE-PHOSPHATASE; MORTALITY RISK;
D O I
10.1053/j.ajkd.2010.02.340
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This commentary provides a US perspective on the 2009 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). KDIGO is an independent international organization with the primary mission of the promotion, coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines for the care of patients with kidney disease. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI), recognizing that international guidelines need to be adapted for each country, convened a group of experts to comment on the application and implementation of the KDIGO guideline for patients with CKD in the United States. This commentary puts the KDIGO guideline into the context of the supporting evidence and the setting of care delivered in the United States and summarizes important differences between prior KDOQI guidelines and the newer KDIGO guideline. It also considers the potential impact of a new bundled payment system for dialysis clinics. The KDIGO guideline addresses the evaluation and treatment of abnormalities of CKD-MBD in adults and children with CKD stages 3-5 on long-term dialysis therapy or with a kidney transplant. Tests considered are those that relate to laboratory, bone, and cardiovascular abnormality detection and monitoring. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease in patients with CKD stages 3-5D and 1-5T. Limitations of the evidence are discussed. The lack of definitive clinical outcome trials explains why most recommendations are not of level 1 but of level 2 strength, which means weak or discretionary recommendations. Suggestions for future research highlight priority areas. Am J Kidney Dis 55:773-799. (C) 2010 by the National Kidney Foundation, Inc.
引用
收藏
页码:773 / 799
页数:27
相关论文
共 88 条
[1]   Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].
Agarwal, R ;
Acharya, M ;
Tian, J ;
Hippensteel, RL ;
Melnick, JZ ;
Qiu, P ;
Williams, L ;
Batlle, D .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828
[2]   Vitamin D and kidney disease [J].
Al-Badr, Wisam ;
Martin, Kevin J. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (05) :1555-1560
[3]   Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration [J].
Al-Hejaili, F ;
Kortas, C ;
Leitch, R ;
Heidenheim, AP ;
Clement, L ;
Nesrallah, G ;
Lindsay, RM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :2322-2328
[4]   CALCIUM KINETICS AND THE LONG-TERM EFFECTS OF LOWERING DIALYSATE CALCIUM-CONCENTRATION [J].
ARGILES, A ;
KERR, PG ;
CANAUD, B ;
FLAVIER, JL ;
MION, C .
KIDNEY INTERNATIONAL, 1993, 43 (03) :630-640
[5]  
Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
[6]   Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients [J].
Bervoets, ARJ ;
Spasovski, GB ;
Behets, GJ ;
Dams, G ;
Polenakovic, MH ;
Zafirovska, K ;
Van Hoof, VO ;
De Broe, ME ;
D'Haese, PC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (05) :997-1007
[7]   The 2009 Proposed Rule for Prospective ESRD Payment: Perspectives From a For-Profit Small Dialysis Organization [J].
Bhat, J. Ganesh ;
Bhat, Premila .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (02) :231-233
[8]   25-Hydroxyvitamin D Measurement, 2009: A Review for Clinicians [J].
Binkley, Neil ;
Krueger, Diane ;
Lensmeyer, Gary .
JOURNAL OF CLINICAL DENSITOMETRY, 2009, 12 (04) :417-427
[9]   High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death [J].
Blayney, Margaret J. ;
Pisoni, Ronald L. ;
Bragg-Gresham, Jennifer L. ;
Bommer, Juergen ;
Piera, Luis ;
Saito, Akira ;
Akiba, Takashi ;
Keen, Marcia L. ;
Young, Eric W. ;
Port, Friedrich K. .
KIDNEY INTERNATIONAL, 2008, 74 (05) :655-663
[10]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218